secwatch.observer — SEC 8-K summary
======================================

Issuer:     NAVIDEA BIOPHARMACEUTICALS, INC. (—)
CIK:        0000810509
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001437749-23-011528
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.03, 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Navidea secures up to $10.75M via milestone sale, equity line, and bridge note
------------------------------------------------------------------------------

- LOI to sell Cardinal milestone payment (due when Lymphoseek sales exceed $100M) for $8M.
- Entered $2.75M common stock purchase agreement with Keystone; 400K commitment shares issued.
- Received $225K advance under $300K secured bridge note from Vice Chairman John K. Scott Jr.
- Proceeds to fund Phase IIb (NAV3-32) and Phase III (NAV3-33) trials and working capital.
- Bridge note matures June 26, 2023; secured by all company assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/810509/000143774923011528/0001437749-23-011528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/810509/000143774923011528/navb20230427_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-011528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer